Patients with obstructive sleep apnea (OSA) experience insulin resistance and
its clinical consequences, including hypertriglyceridemia, reduced high density
lipoprotein-associated cholesterol (HDL-c), visceral adiposity, hepatic
steatosis, increased epicardial fat thickness, essential hypertension, glucose
intolerance, increased risk for type 2 diabetes, chronic kidney disease,
subclinical vascular damage, and increased risk for cardiovascular events.
Obesity is a major contributor to OSA. The prevalence of OSA is almost universal
among patients with severe obesity undergoing bariatric surgery. However, insulin
resistance and its clinical complications occur in OSA patients irrespective of
general obesity (body mass index). In OSA patients, apnea episodes during sleep
induce oxyhemoglobin desaturation and tissue hypoxia. Insulin resistance is an
adaptive response to tissue hypoxia and develops in conditions with limited
tissue oxygen supply, including healthy subjects exposed to hypobaric hypoxia
(high altitude) and OSA patients. Indicators of oxyhemoglobin desaturation have
been robustly and independently linked to insulin resistance and its clinical
manifestations in patients with OSA. Insulin resistance mediates the elevated
rate of type 2 diabetes, chronic kidney disease, and cardiovascular disease
unexplained with traditional cardiovascular risk factors present in OSA patients.
Pathophysiological processes underlying hypoxia-induced insulin resistance
involve hypoxia inducible factor-1 upregulation and peroxisome
proliferator-activated receptor-gamma (PPAR-
) downregulation. In human
adipose tissue, PPAR-
activity promotes glucose transport into
adipocytes, lipid droplet biogenesis, and whole-body insulin sensitivity.
Silencing of PPAR-
in the adipose tissue reduces glucose uptake and fat
accumulation into adipocytes and promotes insulin resistance. In conclusion,
tissue hypoxia drives insulin resistance and its clinical consequences in
patients with OSA, regardless of body mass index.